HBsAg,HCV-Ag和AFP在肝硬变和肝细胞癌组织中的表达  

Expression of HBsAg,HCV-Ag and AFP in liver cirrhosis and hepatocarcinoma

作　　者：翟守恒 刘俊彬 刘云梅[1] 张玲莉[1] 杜志平 

机构地区：[1]中国人民解放军264医院传染科,山西省太原市030001 [2]中国人民解放军第四军医大学西京医院临床免疫科,陕西省西安市710032

出　　处：《世界华人消化杂志》2000年第5期524-527,共4页World Chinese Journal of Digestology

摘　　要：目的探讨 HBsAg,HCV-Ag 和 AFP 在抗肝癌免疫应答中的意义.方法用免疫组织化学 APA 法检测 HBsAg,HCV-Ag 和 AFP在肝硬变和肝细胞癌中的表达、定位和分布.结果在 LC 组织中,HBsAg 为53.3%(16/30),HCV-Ag 为63.3%(19/30).AFP 为26.7%(8/30);在 HCC 组织中,HBsAg 为17.5%(7/40),HCV-Ag 为52.5%(21/40),AFP 为45.0%(18/40);在癌周围组织(PCT)中,HBsAg 为65.6%(21/32),HCV-Ag 为50.0%(16/32),AFP 为3.1%(1/32);统计学处理显示,在 HCC 组织中,HBsAg 阳性率显著低于 LC(x^2=9.977,P<0.01)和 PCT(x^2=17.325,P<0.01);HCV-Ag 阳性率与 LC 和 PCT 无显著差异;AFP 阳性率显著高于PCF(x^2=16.048,P<0.01),与 LC 无显著差异.结论 HHsAg,HCV-Ag 和 AFP 与肝癌的发生有密切的关系,AFP 可能是 CTL 攻击的主要靶抗原.但血清中高浓度的 AFP可能阻断了 CTL 的作用.因此,用足量的抗 AFP 抗体来治疗AFP 阳性肝癌可能是一条有希望的途径.AIM To probe into the significance of expression of HBsAg,HCV-Ag and AFP in anti-tumor immune response to hepatocarcinoma. METHODS Immunohistochemical APA technique was used to study the expression,location and distribution of these antigens. RESULTS In liver cirrhosis the positive rate of HBsAg, HCV-Ag and AFP was 53.3% (16/30),63.3% (19/30) and 26.7% (8/30),respectively.In human hepatcearcinoma, the positive rate of HBsAg,HCV-Ag and AFP was 17.5% (7/40),52.5%(21/40) and 45.0%(18/40),respectively. In pericancerous tissue (PCT),the positive rate of HBsAg,HCV-Ag and AFP was 65.6% (21/32),50.0% (16/32) and 3.1% (1/32),respectively.Statistical analysis suggested that the positive rate of HBsAg was significantly lower in hepatocarcinoma than that in liver cirrhosis (x^2=9.977,P<0.01) and in PCT (x^2=17.325, P<0.01).No significant difference was found in the positive rate of HCV-Ag between HCC and LC and PCT. The positive rate of AFP in HCC was significantly higher than that in PCT (x^2=16.048,P<0.01),but no significant difference was found between HCC and LC. CONCLUSION HBsAg,HCV-Ag and AFP were closely related to the occurrence of hepatocarcinoma.AFP might be the main target antigen for CTL,but high level serum AFP might repress the function of CTL to tumor cells. Therefore,sufficient anti-AFP antibody may be a hopeful therapy for hepatocarcinoma patients whose serum AFP was positive.

关 键 词：肝硬化 肝肿瘤 免疫组织化学 抗原 治疗学 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学] R735.7